个体化风险预测工具在前列腺癌主动监测患者中的临床评估
本研究连续纳入大型机构主动监测项目中的男性,在风险预测工具实施前(n=36)和实施后(n=31)分别于常规访视前后进行问卷调查,评估感知癌症控制、活检相关焦虑和癌症信息负担。结论认为提供个体化预测有助于患者更好理解癌症风险。
要点
- 工具未显著改变活检相关焦虑和癌症信息负担。
- 患者对工具满意且理解程度中等,可考虑在其他临床站点推广。
核心结论
- 为主动监测患者提供个体化预测有助于其更好理解癌症风险,应考虑在其他临床站点使用。
研究设计与样本
- 连续招募大型机构主动监测项目中的男性,风险预测工具实施前36例、实施后31例。
- 两组均在常规访视前后接受问卷调查,比较访视前后变化。
主要发现
- 活检相关焦虑和癌症信息负担在两组间无显著差异。
- 干预期患者对工具满意,理解程度中等。
临床怎么用
- 在主动监测随访中可考虑向患者展示个体化风险预测,以改善其对癌症风险的理解和感知控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether providing individualized predictions of health outcomes to men on active surveillance (AS) alleviates cancer-related anxiety and improves risk understanding. MATERIALS AND METHODS: We consecutively recruited men from our large, institutional AS program before (n = 36) and after (n = 31) implementation of a risk prediction tool. Men in both groups were surveyed before and after their regular visits to assess their perceived cancer control, biopsy-specific anxiety, and burden from cancer-related information. We compared pre-/post-visit differences between men who were and were not shown the tool using two-sample t-tests. Satisfaction with and understanding of the predictions were elicited from men in the intervention period. RESULTS: Men reported a relatively high level of cancer control at baseline. Men who were not shown the tool saw a 6.3 point increase (scaled from 0 to 100) in their perceived cancer control from before to after their visit whereas men who were shown the tool saw a 12.8 point increase, indicating a statistically significant difference between groups (p = .04). Biopsy-specific anxiety and burden from cancer information were not significantly different between groups. Men were satisfied with the tool and demonstrated moderate understanding. CONCLUSION: Providing individualized predictions to men on AS helps them better understand their cancer risk and should be considered at other clinical sites.
引用
- Huntley JH, Coley RY, Carter HB, et al. Clinical Evaluation of an Individualized Risk Prediction Tool for Men on Active Surveillance for Prostate Cancer. Urology. 2018. PMID: 30171924. doi:10.1016/j.urology.2018.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。